Company Presentation 1Q26

PT Soho Global Health Tbk

SOHO IJ / SOHO.JK

June 2026

Disclaimer

This presentation has been prepared as general information material regarding PT Soho Global Health Tbk ("Company") and may not be modified, in whole or in part, without prior consent from the Company. This presentation is provided for informational purposes only and shall not be relied upon as a basis for making any investment decision. The delivery of this presentation does not constitute a recommendation or financial advice of any kind. The Company makes no representation or warranty, whether express or implied, as to the accuracy, completeness, or fairness of the information contained herein. This presentation has been prepared based on the Consolidated Financial Statements for the Financial Year ended on **March 31, 2026**. This presentation does not contain all information that may be material to the investment decision of investors or prospective investors. The information contained in this presentation is based on conditions, data, and assumptions available at the time of preparation, which are subject to change at any time. The Company may update or amend the information contained in this presentation to reflect changes in circumstances or the availability of new or additional information, which may be made without prior notice to the public. However, the Company is under no obligation to update or revise any information contained in this presentation, whether as a result of new information, future events, or otherwise, except as required under applicable capital markets laws and regulations. Therefore, each recipient of this presentation material must carry out an independent analysis (including consulting with legal, tax, business and/or financial advisors) of the business, operations, financial condition and everything related to the Company, including investment decisions in the Company. Each recipient must also conduct a separate review of the adequacy, accuracy and completeness of all information relating to the Company, because the information and data in this presentation material is not a substitute for independent evaluation and analysis. This presentation material is not an offer document to sell or issue, or an invitation to buy or inducement to buy, acquire or obtain any shares, securities, assets and / or liabilities of the Company or its subsidiary, joint venture or its affiliates or a call to enter in investment activities. Any decision to buy or subscribe for any shares, securities, assets and/or liabilities of the Company or its subsidiary, joint venture or its affiliates should be made after seeking appropriate professional advice. The Company is not responsible for your own assessment of this presentation material

All statements other than statements of historical facts that included in this presentation, which are not limited to the Company's financial position, business strategy, management plans and objectives for future operations (including development plans, objectives relating to the Company's products and services, and anticipated product launches) are forward-looking statements ("projections"), are based on various assumptions about the Company's current and future strategies and the environment in which the Company will operate in the future. Those statements are projected hopes and expectations in the future, which represents the Company's current circumstances with possible events in the future and financial planning. Such projections are only stated at the date of this presentation and are based on assumptions and available data at the time this presentation is created, therefore the projections are containing risks and subject to change at any time. Actual results may differ from those expressed or implied in such projections. The Company expressly releases any obligations or reflections of any changes in the Company's expectations in connection with these matters, or any changes in the various events, conditions or circumstances on which each projection is based. Market data and certain industry forecasts used in this presentation are obtained from market research, publicly available information and industry publications that have not been independently verified, so the Company is not responsible for the accuracy of such information. Company or related parties will not be liable in any way for any consequences (including but not limited to any direct, indirect, or consequential losses) arising from or relating to any reliance on or use of the content of this presentation

Table of Content

Company Overview 4

Financial Highlights and Key Strategies 7

Business Updates

- Consumer health 10
- Alliance 14
- Distribution 17

Financial Updates 20

Appendix 26

Company Overview



Overview

Our Core Business Segment

We are a leading healthcare company in Indonesia with strong consumer health brands across categories and demographics

#1

Number one vitamin company in Indonesia*

Consumer Health

Trusted, high-quality preventive, curative & wellness products to support everyday health

ASTHIN · BOOST · CURCUMA · Curcuma Plus · DIAPET · FITKOM · IMBOOST · IMBOOST FORCE · LAXING · Lelap · NOROID

#2

Number two company in Indonesia OTC Healthcare market*

Alliance

In-licensing of global prescription pharmaceutical products through strategic collaborations

ANGELINI PHARMA · Baxter · CONCORD BIOTECH *Biotech for Mankind...* · ESSENTIAL PHARMA · Genetic QUALITY, SAFETY, EFFICACY · GILEAD · J&J · MACLEODS · Panacea Biotec *Innovation in support of life* · sanofi · WM

Distribution

Nationwide distribution enabling owned product prioritization while providing 3rd party services to achieve economies of scale

Amarox · azarine · B|BRAUN · BAUSCH+LOMB · BERNOFARM PHARMACEUTICAL COMPANY · CAA PT CITRA ALAM AROMINDO · Eisai · FAHRENHEIT PT PRATAPA NIRMALA · FRESENIUS MEDICAL CARE · HALEON · IDSMED · KALBE · kenvue · L'ORÉAL · PARVUS

**excluding RTD*
Brand, partner, and principal names are arranged in alphabetical order
Source: IQVIA MAT 4Q25

Overview

Company and Product Milestone

A legacy of growth, powered by innovation and passion

Early Years

1946
Founded by Mr. Tan Tjhoen Lim as an injectable products focused pharma company

1956
Established PT Parit Padang as the distribution arm of the business

1992
Started to market OTC products

Transformation Years

2013
New management team onboarded

2014
Imboost OTC switch

2015
Partnership with Quadria Capital

2017
rolled out SAP as the new ERP system

2019
- Launched Epclusa (the 1st in-licensed product)
- Launched Imboost Effervecent
- Introduced PPGOS, B2B app, digitalized distribution

Listed 2020

IDX

- CVC invested in SOHO
- Launched Curcuma Force
- Launched Soroquin

Product Launches and Expansions

2021
- Launched Imboost Extra Vit.C & D3
- Launched Imboost Force Ultimate
- Launched Pramifrol

2022
- Launched Gastin Force
- Launched Imboost Bone

2023
- Launched Fitkom Calcigrow
- Launched Curcuma Plus Vit Grow tablet

2024
- Launched Imboost Force Cough
- Launched Boost Protekid
- Launched Noroid small packs
- Signed 6 new products for the alliance portfolio
- Launched Mycophen, Tacsograf, Carlepone

2025
- Signed J&J full agency deal
- Signed 14 new products and launched Pacliall
- PPGOS released ver. 3.0

2026
Launched Imboost Force FCT+

Onwards
Accelerating New Product Development (NPD) pipeline, alliance partnerships, and investment in digital capabilities

color code: consumer health | alliance | distribution

Financial Highlights and Key Strategies







BOOST ProteKid

Financial Highlights

Net Revenues and EBITDA

Consumer health and alliance continue to dominate the profitability profile and growth

	Profile	Bridge	Key Updates
Net Revenues **-1.3%** **Growth** *(YTD yoy)*			• Group net revenues decline driven by a slight reduction in the distribution business due to the loss of a few principals that we are working to replace • Consumer health and alliance segment continued to record strong growth segments, gaining share in the vitamin and supplement category, as well as leveraging strategic partnerships
EBITDA **+32.8%** **Growth** *(YTD yoy)*			

Financial Highlights

Key Strategies

Drive growth, innovation, and shareholder value

Consumer Health

- Accelerate growth across **brands** and **channels**
- Leverage digital marketing to drive **awareness and conversion**
- Innovate in **preventive health** and **beauty**

Alliance

- Expand **in-licensing partnerships** and **portfolio**
- Drive growth through **new launches** and **e-catalog participation**

Distribution

- Selectively add **strategic principals** with **attractive margins**
- Scale **digital distribution** through PPGOS 3.0
- Focus on **efficiency**, especially operating expense and working capital

Business Updates

Consumer Health





Lelap®

Consumer Health

Multiple Category Leading Brands

A diversified portfolio continues to strengthen our market position

Body Defense

IMBOOST


Imboost Extra Vit C & D3


Imboost Bone


Imboost Cough Adult


Imboost Cough Kids


Imboost Tablet


Imboost Kids Syrup


Imboost Kids Chewy Tablet


Imboost Effervescent

IMBOOST FORCE


Imboost Force FCT+


Imboost Force


Imboost Force Ultimate


Imboost Force Cough Kids


Imboost Force Syrup


Imboost Force Extra Strength

Children's multivitamin

Curcuma Plus


Curcuma Plus Grow


Curcuma Plus Sharpy


Curcuma Plus Appetite


Curcuma Plus Imuns


Curcuma Plus Fruit & Veggie


Curcuma Plus Go Talz


Curcuma Plus Honey Vit/Bumin


Curcuma Plus Milk


Curcuma Plus Grow Tablet

BOOST ProteKid


Boost Protekid

FITKOM


Fitkom Hi-C


Fitkom Tablet Multivitamin


Fitkom Calcigrow


Fitkom + Immuno


Fitkom Gummy Multivitamin


Fitkom Gummy Fruit & Vegie


Fitkom Gummy Vit C & Zinc


Fitkom Gummy Strawberry Milk

Gastro-hepatology

CURCUMA


Curcuma Force


Curcuma tab Blister


Bio-Curliv


Curliv Plus


Curliv Plus Syrup


BioCurkem

Multi-vitamin

BOOST


Boost D 1000 IU


Boost D 5000 IU

and many other brands

Anti Diarrheal

DIAPET

Diapet

Diapet Anak

Laxatives

LAXING

Sleep Aid

Lelap®

Adult Antioxidant Supplements

ASTHIN

Asthin B-OND

Asthin B-OND 6

Astraderm Gel

Astraderm Cream

Asthin Force 12

Asthin Force 6

Asthin Force 4

Dermatology

NOROID®

Noroid Cream, Lotion & Derma Rash Cream

Noroid Soothing Face Moisturiser

Consumer Health


Shift Marketing Focus to Digital and Introduce New Products

Accelerate growth through digital capability and product development in higher growth categories

Digital In-House Capabilities



Expand digital native team



Add livestreaming/ content studios







Enhance content creation capabilities and Leverage KOLs and affiliates networks

Strategy

- Accelerate growth across brands and channels
- Leverage digital marketing to drive awareness and conversion
- Innovate in preventive health and beauty

Drive Awareness & Consideration

Conversion to Product Purchases

Online channels
engagement and purchase

Offline channels
distribution and visibility

Omnichannel Presence

E-commerce | Pharmacy | Modern Trade | Hospital


Consumer Health

Continued Double-Digit Growth


Consumer health continued to record strong and faster than market growth

Segment Results


**value in IDR billion*




Revenues
+ 30.9%



Gross Profit
+ 33.9%



EBITDA[a]
+ 53.7%



Operating Profit[b]
+ 55.8%

Commentary

- Revenues increased, driven by strong growth in both kids and adult vitamins & supplements categories, especially in on-line channels
- Revenues growth was primarily volume-driven, despite selective price increases
- Gross profit margin improved, supported by a favorable product mix
- EBITDA and operating profit growth were driven by continued operating leverage from higher sales volumes and focused investment

[a] *EBITDA = Operating profit + Depreciation + Amortization*
[b] *Operating Profit = Gross profit – Selling exp. – G&A exp. – R&D exp.*

SOHO Global Health

Business Updates

Alliance



Alliance

Leverage In-Licensing Capabilities

Build growth momentum by gaining trust with strategic partners

Portfolio in Various Therapeutic Classification (TC)

- Central Nervous System
- Oncology and Immunology
- Hepatitis
- Respiratory
- Gastrointestinal
- Cardiometabolic
- Others

Strategic Partners

ANGELINI PHARMA, Baxter, CONCORD BIOTECH Biotech for Mankind..., ESSENTIAL PHARMA, Genetic QUALITY. SAFETY. EFFICACY, GILEAD, J&J, MACLEODS, Panacea Biotec Innovation in support of life, sanofi, WM

The names are arranged in alphabetical order

Strategy

- Expand in-licensing partnerships and portfolio
  - Extend primary areas of expertise
  - Grow medical engagement and trust
  - Transfer technology
  - Strict compliance standard
- Lever the scalable national health insurance coverage

Capabilities

- Market Intelligence & Business Development
- Registration
- Commercialization
- Manufacturing


Alliance

Capturing Growth Momentum


Accelerated growth through a new strategic partnership

Segment Results


**value in IDR billion*




Revenues
+ 115.8%



Gross Profit
+ 51.6%



EBITDA[a]
+ 59.1%



Operating Profit[b]
+ 61.7%

Commentary

- Revenues increased, primarily driven by new strategic partnership with J&J
- Gross profit margin declined due to mix, which also impacted operating margins
- EBITDA and operating profit increased strongly, supported by higher sales growth

[a] *EBITDA = Operating profit + Depreciation + Amortization*
[b] *Operating Profit = Gross profit – Selling exp. – G&A exp. – R&D exp.*

Business Updates

Distribution




Distribution

Strong Network and Principal Coverage

Leverage nationwide reach and strategic principals to capture growth opportunities

Network



25 Branches ● *Branches*

3 Sales Offices ● *Sales office*

● *Sub-distributors network*

Third Party Principals

Prescription Pharmaceuticals

Amarox, Bayer, Bernofarm Pharmaceutical Company, Eisai, Fahrenheit PT Pratapa Nirmala, Kalbe, mundipharma, Pharos, PT. Yarindo Farmatama Pharmaceutical Industries

Consumer

azarine, CAA PT Citra Alam Abadindo, Griff Perfume Manufacturer, Haleon, kenvue, L'Oréal, Luxottica

Medical Device

3M, Bausch + Lomb, B Braun, IDSMED, Fresenius Medical Care, Parvus

The names are arranged in alphabetical order

Strategy

- Selectively add strategic principals with attractive margins:
  - Consumer and cosmetic segments
  - Low working capital requirements
- Scale digital distribution through PPGOS 3.0 apps
  - Digital community engagement to pharmacist and frontliners
- Focus on efficiency (operating expenses and working capital)

Focus Area

- Principals Expansion
- Working Capital
- PPGOS 3.0 Apps
- Efficiency Initiatives


Distribution

Focus on Quality Sales and Cost/Capital Efficiency

Optimized principal portfolio and profitability

Segment Results


**value in IDR billion*



Revenues

-7.5%


margin	1Q25	1Q26
	8.5%	8.8%



Gross Profit

-4.5%


margin	1Q25	1Q26
	2.4%	1.9%



EBITDA[a]

-26.2%

margin	1Q25	1Q26
	2.1%	1.6%



Operating Profit[b]

-29.3%

Commentary

- Lower revenues due to principal portfolio discontinuation
- Gross profit margin increase despite the sales decline due to principal mix
- EBITDA and operating profit declined as a result of lower sales and higher G&A expenses

[a] *EBITDA = Operating profit + Depreciation + Amortization*
[b] *Operating Profit = Gross profit – Selling exp. – G&A exp. – R&D exp.*

Financial Updates




IMBOOST FORCE FCT+

Financial Updates

Segment and Consolidation Performances

Focus to grow the higher-margin business while still capturing overall market demand

*value in IDR billion




[a] operating profit = gross profit – selling exp. – G&A exp. – R&D exp.

Financial Updates

Profitability

Improving business mix, driving profitability



Commentary

- Gross profit and margin improved, reflecting our strategic focus on higher-margin businesses
- Disciplined cost management supported profitability improvement
- Continued cost efficiency and operating leverage drove strong EBITDA growth
- Favorable non-operating items further contributed to stronger net profit growth


[a] *operating expenses = selling exp. - G&A exp. - R&D exp.*
[b] *EBITDA = operating profit + depreciation + amortization*

Financial Updates


Healthy Working Capital and Free Cash Flows

Maintaining financial flexibility through disciplined cash and working capital management


Cash Conversion Cycle[a]




Working Capital[b]



Net Cash[c]



Capex & Free Cash Flows(FCF) [d]



Commentary

- Maintained improvement in inventory and payable days
- Stricter terms to some channels with longer term of payments
- Strong net cash position to continue driving growth while returning cash to shareholders
- Positive free cash flow reflects strong operating cash generation and disciplined capital allocation


[a] DOI= inventory/COGS; DOAR= account and other receivables/net sales; DOAP=account payable/COGS; CCC= DOI+DOAR-DOAP; 30 days/month
[b] working capital= account and other receivables – account payable
[c] net cash = cash and cash equivalents + other current financial assets – interest bearing debt
[d] FCF= operating cash flows- tangible capex
all value are expressed in IDR billion, except cash conversion cycle

Financial Updates


Shareholders' Returns

Improved return on equity and consistent dividend payment to maximize shareholders value

Return on Equity (ROE)[a]



Dividend[b] (IDR bn)



Commentary

- ROE has improved over time, reflecting stronger profitability and capital efficiency
- With a focus on maintaining healthy cash flows, dividends have been consistently paid

[a] *ROE = Net Income Attributable for Owners of the Parent Entity divided by Total Equity, presented yearly*
[b] *Dividends are presented based on the fiscal year to which they relate, while the actual payment may occur in the subsequent fiscal year*
Dividend payout ratio (DPR) = Total Annual and Interim Dividend Paid Divided by Net Income Attributable for Owners of the Parent Entity

Financial Updates

2026 Outlook

Strive to continue double-digit profitability growth

Mid to High-Single Digit

Net Revenues Growth

1Q26: -1.3%

Strong Double-Digit

EBITDA Growth

1Q26: +32.8%

~50%

Dividend Payout Ratio Policy

Fiscal Year 2025: 153.5%

Assumptions:
Exchange rate IDR16,500/USD, capital expenditure IDR50 - 55 bn

Kemasan
BARU

Appendix






Curcuma Plus

Appendix

Pharmaceutical Industry Overview


Healthcare relevance in everyday life creates attractive growth opportunities

Pharmaceutical Market



source: IQVIA MAT 4Q25

Healthcare Spending per Capita



source: Frost & Sullivan, WHO GHED

National Health Insurance & Healthcare Budget

National health insurance (JKN) coverage of total population

[a]283 mn people	[b]99.3%

national health budget for 2026

[c] IDR 247 tn	gr. 13% over 2025

a https://data.bpjs-kesehatan.go.id/bpjs-portal/action/dash-publik-detail.cbi?id=22f081ce-419d-11eb-a5e7-b5beb99935c0
b https://kesehatan.djsn.go.id/kesehatan/doc/laporan-bulanan/Monthly_Report_JKN_11_2025.pdf
c https://wip.kemenkeu.go.id/informasi-publik/publikasi/berita-utama/Tingkatkan-Anggaran-Kesehatan-APBN-2026

Opportunity in the Industry

Non-prescribed drugs (non-Rx) market

- **Shifting consumer preference** towards e-commerce channels
- **Lifestyle-related health challenges** continue to drive greater consumption of supplements and OTC remedies
- **Rising health awareness** will drive the shift to prevention instead of curative treatment
- **Increasing ingredient-consciousness** among consumers is driving preference for natural products

Prescribed drugs (Rx) market

- **Increased elderly population** drive the degenerative medication needs
- **Chronic disease** rising incidence
- **Digital health adoption** among healthcare professionals continues to accelerate in the post-COVID era.
- **JKN** to improve access and boost volume for generics

Appendix

ESG initiatives

We continue to strengthen our ESG framework through measurable environmental initiatives, responsible business practices, employee development, and a robust governance framework, supporting sustainable long-term growth

ESG Highlights

- **682 tCO_2e** — Emissions Avoided in 2025
- **6.9%** — Reduction in Factory Energy-to-Production Ratio
- **50%** — Independent Commissioners
- **91%** — Supplier Coverage under Supplier Code of Conduct
- **100%** — Annual Code of Conduct Training Completion
- **100%** — Cybersecurity Training Completion

ESG Policy

PT SOHO GLOBAL HEALTH TBK (GROUP)

East Jakarta - Indonesia | Manufacture of basic pharmaceutical products and pharmaceutical preparation

Company size: **L** | Assessment scope: **Group**

Overall score ↗ **55**/100

Percentile **44th**

COMMITTED ecovadis Sustainability Rating NOV 2025

Ecovadis Rating	Score of 55/100	4 Key Assessment
Recognized for sustainability performance by a prestigious global platform, Ecovadis	Surpassed more than half of the 150,000+ businesses assessed by Ecovadis	• Environment • Labor and human rights • Ethics • Sustainable procurement

Environment

- Renewable energy adoption
- Emissions management
- Initiated scope 3 measurement
- Waste reduction initiatives
- Sustainable product and packaging innovation

Social

- Human rights policy (including non-discrimination, child labor prohibition, prevention of harassment and intimidation)
- Grievance mechanism
- Gender equality
- Corporate social responsibility
- Regular engagement with Labor Union
- Employee development, engagement, and well-being programs
- Annual code of conduct and business ethics training for employees

Governance

General Policies

- Corporate Governance Code
- Code of Conducts and Business Ethics
- Code of Business Ethics and Conduct (external)
- Whistleblowing Program
- Anti-Bribery and Anti-Corruption (ABAC)
- Sustainable Procurement
- Data Privacy Policy

Charter

- BOD
- BOC
- Audit committee
- Nomination and Remuneration Committee

Local and International Certifications for Quality and Management System

Quality, Safety, and Product Responsibility

- Good manufacturing practice and good distribution practice of medicine/traditional medicine
- Good manufacturing practice for cosmetics
- Good processed food production methods
- Good distribution practice of medical devices
- Halal certification
- Local content (TKDN) certification

International Best Practice Compliance

- ISO 9001:2015 Quality Management System
- ISO 14001:2015 Environmental Management Systems
- ISO 45001:2018 Occupational Health and Safety Management System
- ISO 27001:2022 Information Security management systems

Appendix

Profit or Loss

in IDR million

CONSOLIDATED PROFIT OR LOSS	1Q25	1Q26	growth YTD (yoy)
Net Revenue	**2,670,918**	**2,635,637**	**-1.3%**
COGS	(2,220,991)	(2,103,343)	-5.3%
% of net revenue	83.2%	79.8%	
Gross Profit	**449,927**	**532,294**	**18.3%**
% of net revenue	***16.8%***	***20.2%***	
Selling Expenses	(229,711)	(241,399)	5.1%
% of net revenue	*8.6%*	*9.2%*	
G&A Expenses	(38,843)	(47,996)	23.6%
% of net revenue	*1.4%*	*1.8%*	
R&D Expenses	(7,528)	(9,450)	25.5%
% of net revenue	*0.3%*	*0.3%*	
Operating Expenses	**(276,082)**	**(298,845)**	**8.2%**
% of net revenue	***10.3%***	***11.3%***	
Operating Profit	**173,845**	**233,449**	**34.3%**
% of net revenue	***6.5%***	***8.9%***	
Other income	1,054	3,381	220.8%
Other expenses	(5,660)	(372)	-93.4%
Finance income	1,218	5,040	313.8%
Finance costs	(304)	(145)	-52.3%
Income before corporate income tax	**170,153**	**241,353**	**41.8%**
% of net revenue	***6.4%***	***9.2%***	

Appendix

Profit or Loss (Cont'd)

in IDR million

CONSOLIDATED PROFIT OR LOSS	1Q25	1Q26	growth YTD (yoy)
Corporate Income Tax	(36,908)	(51,495)	39.5%
Tax Rate	*21.7%*	*21.3%*	
Other comprehensive income (loss)	-	-	n.a.
Total Comprehensive Income for the period	133,245	189,858	42.5%
Income for The Year	**133,245**	**189,858**	**42.5%**
Income Attributable to owners of the parent entity	**133,245**	**189,858**	**42.5%**
% of net revenue	*5.0%*	*7.2%*	
NCI	-	-	n.a.
Comprehensive Income for The Year	**133,245**	**189,858**	**42.5%**
Income Attributable to owners of the parent entity	133,245	189,858	42.5%
% of net revenue	5.0%	7.2%	44.4%
NCI	-	-	n.a.
Basic EPS	**10**	**15**	**50.0%**

Appendix

Financial Position

in IDR million

CONSOLIDATED FINANCIAL POSITION	FY25	1Q26
ASSETS		
Cash and cash equivalents	1,104,126	818,826
Trade receivables	1,987,071	2,146,728
Other receivables	319,808	390,209
Inventories	1,562,326	1,503,919
Prepaid tax	520,665	272,522
Advances	16,735	13,807
Prepayments	4,012	6,809
TOTAL CURRENT ASSETS	**5,514,743**	**5,152,820**
TOTAL NON-CURRENT ASSETS	**642,744**	**644,361**
TOTAL ASSETS	**6,157,487**	**5,797,181**
LIABILITIES		
CURRENT LIABILITIES		
Trade payables	2,638,441	2,459,293
Other payables	509,359	77,371
Taxes payable	34,984	82,238
Accrued expenses	150,559	144,086
Short-term employee benefits liability	39,326	54,124
Current portion of long-term liabilities:		
Lease Liability	3,720	1,833
TOTAL CURRENT LIABILITIES	**3,376,389**	**2,818,945**
TOTAL NON-CURRENT LIABILITIES	**198,096**	**205,376**
TOTAL LIABILITIES	**3,574,485**	**3,024,321**

Appendix

Financial Position (Cont'd)

in IDR million

CONSOLIDATED FINANCIAL POSITION	FY25	1Q26
EQUITY		
Share capital		
Issued and fully paid	634,584	634,584
Additional paid-in capital	1,061,098	1,061,098
Differences in value of transactions of NCI	(3,662)	(3,662)
Retained earnings:		
Appropriated	126,917	126,917
Unappropriated	723,561	913,419
Other comprehensive income	40,504	40,504
Equity attributable to owners of the parent entity	**2,583,002**	**2,772,860**
Non-controlling Interest	-	-
TOTAL EQUITY	**2,583,002**	**2,772,860**
TOTAL LIABILITIES AND EQUITY	**6,157,487**	**5,797,181**

Appendix

Cash Flows

in IDR million

CONSOLIDATED CASH FLOWS	1Q25	1Q26
CASH FLOWS FROM OPERATING ACTIVITIES		
Cash receipts from customers	2,476,746	2,475,979
Cash payments to suppliers	(2,202,535)	(2,224,084)
Cash payments for salaries,wages and employee benefit	(104,663)	(112,654)
Cash payments for:		
Operating expenses	(257,952)	(309,819)
Tax expenses	(2)	(8,361)
Cash receipts (payments) from other operating activities, net	(4,838)	3,042
Cash receipts from claim for tax refund	288,028	319,660
Net cash provided by operating activities	**194,784**	**143,763**
CASH FLOWS FROM INVESTING ACTIVITIES:		
Receipts from finance income	1,217	5,040
Proceeds from sale of fixed assets	9	868
Payment for advance of right-of-use assets	(7,709)	-
Payment for advance purchases for intangible assets	2,236	-
Acquisition of intangible assets	(2,860)	(310)
Payment for advance purchase for fixed asset	(1,029)	(846)
Acquisition of rights-of-use assets	(4,763)	(4,596)
Purchase of fixed assets	(10,012)	(5,796)
Net cash used in investing activities	**(22,911)**	**(5,640)**

Appendix

Cash Flows (Cont'd)

in IDR million

CONSOLIDATED CASH FLOWS	1Q25	1Q26
CASH FLOWS FROM FINANCING ACTIVITIES:		
Payments of cash dividend	-	(420,095)
Payment of lease liabilities	(1,877)	(3,328)
Decrease (increase) in due from related party, net	5,000	-
Net cash provided by (used in) financing activities	**3,123**	**(423,423)**
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	**174,996**	**(285,300)**
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	**422,446**	**1,104,126**
CASH AND CASH EQUIVALENTS AT END OF PERIOD	**597,442**	**818,826**

Thank You

For more information:
syeren.amanda@sohoglobalhealth.com
Head of Investor Relations

PT Soho Global Health Tbk
Jl. Rawa Sumur II Kav.BB No.3
Kawasan Industri Pulogadung
Jakarta Timur 13930 - Indonesia